Výsledky vyhľadávania - "Irinotecan/therapeutic use"

Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX

Autori: Rompen I. F. Stoop T. F. Van Roessel S. a ďalší

Prispievatelia: Rompen I. F. Stoop T. F. Van Roessel S. a ďalší

Zdroj: Ann Surg

Predmety: neoadjuvant treatment, Male, Adult, adjuvant chemotherapy, FOLFIRINOX, Pancreatic neoplasm, prognostic score, Oxaliplatin/therapeutic use, Irinotecan/therapeutic use, Surgery, anesthesiology, intensive care, radiology, Leucovorin, Fluorouracil/therapeutic use, Irinotecan, Risk Assessment, Pancreatectomy, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Pancreatic Neoplasms/mortality, Humans, Adjuvant, Retrospective Studies, Aged, Cancer och onkologi, Leucovorin/therapeutic use, Pancreatic Ductal/mortality, Kirurgi, Carcinoma, pancreatic neoplasm, Original Articles, Middle Aged, Prognosis, Neoadjuvant Therapy, Pancreatic Neoplasms, Oxaliplatin, Survival Rate, Chemotherapy, Adjuvant, Cancer and Oncology, Surgery, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil, Carcinoma, Pancreatic Ductal

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39886770
http://hdl.handle.net/10138/597981
https://portal.findresearcher.sdu.dk/da/publications/bbb05d5b-17d2-4f47-bbed-9c352fb42524
https://doi.org/10.1097/SLA.0000000000006650
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-235837

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Autori: Lucas Moreno Rebekah Weston Cormac Owens a ďalší

Prispievatelia: Lucas Moreno Rebekah Weston Cormac Owens a ďalší

Zdroj: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Instituto de Investigación Sanitaria La Fe (IIS La Fe)
Journal of clinical oncology, Vol. 42, no.10, p. 1135-1145 (2024)
Journal of Clinical Oncology, Vol. 42, no. 10, p. 1135-1145 (2024)
Moreno, Lucas; Weston, Rebekah; Owens, Cormac; Valteau-Couanet, Dominique; Gambart, Marion; Castel, Victoria; Zwaan, C Michel; Nysom, Karsten; Gerber, Nicolas; Castellano, Aurora; Laureys, Genevieve; Ladenstein, Ruth; Rössler, Jochen; Makin, Guy; Murphy, Dermot; Morland, Bruce; Vaidya, Sucheta; Thebaud, Estelle; van Eijkelenburg, Natasha; Tweddle, Deborah A; ... (2024). Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(10), pp. 1135-1145. American Society of Clinical Oncology 10.1200/JCO.23.00458 <http://dx.doi.org/10.1200/JCO.23.00458>
Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN) 2024, 'Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma : Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 42, no. 10, pp. 1135-1145. https://doi.org/10.1200/JCO.23.00458

Predmety: Adult, Irinotecan/therapeutic use, Adolescent, Neuroblastoma/pathology, Neuroblastoma - Tractament, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, 610 Medicine & health, Bevacizumab/adverse effects, Irinotecan, Quimioteràpia combinada, Local/drug therapy, Young Adult, Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols, Temozolomide, Humans, Preschool, Child, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Temozolomide/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma, Infant, ORIGINAL REPORTS, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Neuroectodermal Tumors, Primitive::Neuroectodermal Tumors, Primitive, Peripheral::Neuroblastoma, 3. Good health, Bevacizumab, Dacarbazine, Neoplasm Recurrence, Local/drug therapy, n/a, Neoplasm Recurrence, Dacarbazine/adverse effects, Child, Preschool, Neoplasm Recurrence, Local, Topotecan, Topotecan/adverse effects

Popis súboru: application/pdf; text

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38190578
https://hdl.handle.net/11351/11285
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=23110
https://research.manchester.ac.uk/en/publications/944d5674-73a6-4896-aa91-1f66999478f5
https://doi.org/10.1200/JCO.23.00458
https://hdl.handle.net/2078.1/301498
https://hdl.handle.net/2078.1/298291
https://boris.unibe.ch/191348/
https://eprints.soton.ac.uk/485710/

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

Autori: Goetze, Thorsten O. Reichart, Alexander Bankstahl, Ulli S. a ďalší

Zdroj: Ann Surg Oncol

Predmety: Male, Adult, Leucovorin, Pancreatic Tumors, Middle Aged, Irinotecan, Prognosis, Deoxycytidine, Gemcitabine, FOLFIRINOX, Leucovorin/administration, Aged [MeSH], Pancreatic Neoplasms/pathology [MeSH], Deoxycytidine/administration, Oxaliplatin/therapeutic use [MeSH], Irinotecan/therapeutic use [MeSH], Neoadjuvant Therapy [MeSH], Male [MeSH], Adenocarcinoma/drug therapy [MeSH], Adenocarcinoma/pathology [MeSH], Pancreatectomy [MeSH], Pancreatic Neoplasms/surgery [MeSH], Fluorouracil/administration, Oxaliplatin/administration, Female [MeSH], Follow-Up Studies [MeSH], Leucovorin/therapeutic use [MeSH], Adult [MeSH], Humans [MeSH], Irinotecan/administration, Middle Aged [MeSH], Neoadjuvant, Pancreatic Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Gemcitabine [MeSH], Survival Rate [MeSH], Chemotherapy, Adjuvant [MeSH], Resectable pancreatic cancer, Adjuvant, Deoxycytidine/analogs, Prognosis [MeSH], Adenocarcinoma/mortality [MeSH], Adenocarcinoma/surgery [MeSH], Neoadjuvant Therapy, Pancreatic Neoplasms, Oxaliplatin, Survival Rate, 03 medical and health sciences, Pancreatectomy, 0302 clinical medicine, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Fluorouracil, Aged, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38459418
https://repository.publisso.de/resource/frl:6502185

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial: a multicentre, randomised, phase 2 trial

Autori: Knut Jørgen Labori Svein Olav Bratlie Bodil Andersson a ďalší

Zdroj: The Lancet Gastroenterology & Hepatology. 9:205-217

Predmety: Oxaliplatin/therapeutic use, Irinotecan/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Neoadjuvant Therapy/adverse effects, Carcinoma, Leucovorin, Fluorouracil/adverse effects, Adenocarcinoma, Irinotecan, 16. Peace & justice, Gemcitabine, Leucovorin/adverse effects, Neoadjuvant Therapy, 3. Good health, Pancreatic Neoplasms, Oxaliplatin, Pancreatic Neoplasms/drug therapy, Adenocarcinoma/drug therapy, Pancreatic Ductal/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Humans, Fluorouracil, Capecitabine, Carcinoma, Pancreatic Ductal

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38237621
https://portal.findresearcher.sdu.dk/da/publications/893612f8-7208-4f68-ac90-bc1b6ce3bcb3
https://doi.org/10.1016/S2468-1253(23)00405-3

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

Autori: Hans-Joachim Schmoll Julia Mann Fabian Meinert a ďalší

Zdroj: Br J Cancer

Predmety: Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, 692/4028/67/1504/1885/1393, Humans [MeSH], Colorectal Neoplasms/drug therapy [MeSH], Bevacizumab/therapeutic use [MeSH], 692/4028/67/1059/602, Irinotecan/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Randomized Controlled Trials as Topic [MeSH], 692/4028/67/1059/99, Article, Quality of Life [MeSH], Colorectal Neoplasms/pathology [MeSH], article, Humans, Colorectal Neoplasms, Irinotecan, 3. Good health, Randomized Controlled Trials as Topic

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37996507
https://repository.publisso.de/resource/frl:6520383

Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)

Autori: Modest, Dominik Paul Heinemann, Volker Schütt, Philipp a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, 0301 basic medicine, ddc:610, Cross-Over Studies, Research, Leucovorin/administration, Oxaliplatin, Aged [MeSH], Pancreatic Neoplasms/pathology [MeSH], Progression-Free Survival [MeSH], Oxaliplatin/therapeutic use [MeSH], Metastatic, Camptothecin/analogs, Irinotecan/therapeutic use [MeSH], Camptothecin/therapeutic use [MeSH], FOLFIRI, Male [MeSH], Camptothecin/administration, Pancreatic cancer, Fluorouracil/administration, Oxaliplatin/administration, Female [MeSH], Fluoropyrimidine, Leucovorin/therapeutic use [MeSH], Adult [MeSH], Fluorouracil/therapeutic use [MeSH], Humans [MeSH], Irinotecan/administration, Middle Aged [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Cross-Over Studies [MeSH], Chemotherapy, Leucovorin, Middle Aged, Irinotecan, Progression-Free Survival, Pancreatic Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Camptothecin, Fluorouracil, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38951245
https://repository.publisso.de/resource/frl:6501324

Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX

Autori: Thomas F. Stoop Toshitaka Sugawara Atsushi Oba a ďalší

Zdroj: JAMA Oncology
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)

Predmety: Male, Adult, Leucovorin/therapeutic use, Oxaliplatin/therapeutic use, Irinotecan/therapeutic use, Leucovorin, Middle Aged, Adenocarcinoma, Fluorouracil/therapeutic use, Irinotecan, Pancreatic Neoplasms, Oxaliplatin, SDG 3 - Good Health and Well-being, Adenocarcinoma/drug therapy, Pancreatic Neoplasms/drug therapy, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil, Adjuvant, Retrospective Studies, Aged

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39847363
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11158

Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis

Autori: Krijn P van Lienden Quintus Molenaar Ronald M. van Dam a ďalší

Zdroj: Annals of Surgery, 274, 5, pp. 729-735

Predmety: Male, Oxaliplatin/therapeutic use, Irinotecan/therapeutic use, SURGERY, IMPACT, Leucovorin, Netherlands/epidemiology, Antineoplastic Agents, Pancreas/pathology, Fluorouracil/therapeutic use, Irinotecan, 03 medical and health sciences, Pancreatectomy, 0302 clinical medicine, SDG 3 - Good Health and Well-being, QUALITY-OF-LIFE, Antineoplastic Combined Chemotherapy Protocols, Humans, Pancreatic Neoplasms/diagnosis, resection, Prospective Studies, Propensity Score, NEOADJUVANT THERAPY, Pancreas, BORDERLINE, Neoplasm Staging, Netherlands, Survival Rate/trends, OUTCOMES, Leucovorin/therapeutic use, Antineoplastic Agents/therapeutic use, ADENOCARCINOMA, Middle Aged, Radboudumc 14: Tumours of the digestive tract RIHS: Radboud Institute for Health Sciences, locally advanced pancreatic cancer, 3. Good health, Pancreatectomy/methods, FOLFIRINOX, Oxaliplatin, Pancreatic Neoplasms, Survival Rate, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil, Surgery - Radboud University Medical Center, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/34334641
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/239076
https://doi.org/10.1097/SLA.0000000000005120
https://pure.eur.nl/en/publications/74f5b12b-d076-4c09-9054-6462852b6612
https://doi.org/10.1097/SLA.0000000000005120
https://research.rug.nl/en/publications/879dd244-9b84-48da-b3fe-2dc2b8df7b87
https://doi.org/10.1097/SLA.0000000000005120
https://hdl.handle.net/11370/879dd244-9b84-48da-b3fe-2dc2b8df7b87
https://pubmed.ncbi.nlm.nih.gov/34334641/
https://research.rug.nl/en/publications/survival-benefit-associated-with-resection-of-locally-advanced-pa
https://pure.amsterdamumc.nl/en/publications/dba02f12-bfaa-421a-b159-fb3badf7fee1
https://doi.org/10.1097/SLA.0000000000005120
https://hdl.handle.net/2066/239076
https://repository.ubn.ru.nl//bitstream/handle/2066/239076/239076.pdf

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel

Autori: L. Sams S. Kruger V. Heinemann a ďalší

Zdroj: Clin Transl Oncol

Predmety: CD4-Positive T-Lymphocytes, Male, Paclitaxel, Leucovorin, Forkhead Transcription Factors, CD8-Positive T-Lymphocytes, Middle Aged, Immune Checkpoint Proteins, Irinotecan, Deoxycytidine, 3. Good health, Oxaliplatin, Pancreatic Neoplasms, Brief Research Article, 03 medical and health sciences, 0302 clinical medicine, Albumins, FOLFIRINOX, Aged [MeSH], T-Lymphocytes, Regulatory/chemistry [MeSH], Gemcitabine, CD4-Positive T-Lymphocytes/drug effects [MeSH], Progression-Free Survival [MeSH], Albumins/therapeutic use [MeSH], CD8-Positive T-Lymphocytes/drug effects [MeSH], Forkhead Transcription Factors [MeSH], Immune Checkpoint Proteins/analysis [MeSH], Oxaliplatin/therapeutic use [MeSH], Programmed Cell Death 1 Receptor/drug effects [MeSH], Irinotecan/therapeutic use [MeSH], CD4-Positive T-Lymphocytes/chemistry [MeSH], Male [MeSH], Nab-paclitaxel, CD8-Positive T-Lymphocytes/chemistry [MeSH], Hepatitis A Virus Cellular Receptor 2/analysis [MeSH], Pancreatic cancer, Carcinoma, Pancreatic Ductal/immunology [MeSH], Female [MeSH], Leucovorin/therapeutic use [MeSH], Immune checkpoints, Fluorouracil/therapeutic use [MeSH], Humans [MeSH], Prospective Studies [MeSH], Middle Aged [MeSH], T-Lymphocytes, Regulatory/drug effects [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], Programmed Cell Death 1 Receptor/analysis [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Pancreatic Neoplasms/immunology [MeSH], Carcinoma, Pancreatic Ductal/drug therapy [MeSH], Immune Checkpoint Proteins/drug effects [MeSH], Paclitaxel/therapeutic use [MeSH], Deoxycytidine/analogs, Pilot Projects [MeSH], Deoxycytidine/therapeutic use [MeSH], Regulatory T cells, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Fluorouracil, Hepatitis A Virus Cellular Receptor 2, Aged, Carcinoma, Pancreatic Ductal

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s12094-021-02620-x.pdf
https://pubmed.ncbi.nlm.nih.gov/33876417
https://dialnet.unirioja.es/servlet/articulo?codigo=8064032
https://link.springer.com/content/pdf/10.1007/s12094-021-02620-x.pdf
https://link.springer.com/article/10.1007/s12094-021-02620-x
https://www.ncbi.nlm.nih.gov/pubmed/33876417
https://epub.ub.uni-muenchen.de/76493/
http://www.ncbi.nlm.nih.gov/pubmed/33876417
https://repository.publisso.de/resource/frl:6445608
https://epub.ub.uni-muenchen.de/76493/

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer

Autori: Hyeong Seok Lim Sae-Won Han Yong Sang Hong a ďalší

Prispievatelia: Hyeong Seok Lim Sae-Won Han Yong Sang Hong a ďalší

Zdroj: Investigational New Drugs. 39:1335-1347

Predmety: Adult, Male, Maximum Tolerated Dose, Metabolic Clearance Rate, Antineoplastic Agents, Kaplan-Meier Estimate, Antineoplastic Agents / therapeutic use, Irinotecan, Benzophenones / therapeutic use, Colorectal Neoplasms / pathology, Dose-Response Relationship, Benzophenones, 03 medical and health sciences, Benzophenones / adverse effects, 0302 clinical medicine, Valine / analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Valine / adverse effects, Humans, Valine / administration & dosage, Irinotecan / therapeutic use, Neoplasm Metastasis, Valine / therapeutic use, Aged, Vascular-disrupting agent, CKD-516, Antineoplastic Agents / administration & dosage, Dose-Response Relationship, Drug, Antineoplastic Agents / adverse effects, Valine, Middle Aged, Colorectal Neoplasms / drug therapy, Colorectal cancer, Progression-Free Survival, 3. Good health, Benzophenones / administration & dosage, Valine / pharmacokinetics, Area Under Curve, Female, Drug, Benzophenones / pharmacokinetics, Colorectal Neoplasms, Antineoplastic Agents / pharmacokinetics, Half-Life

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/33829355
https://link.springer.com/article/10.1007/s10637-021-01110-9
https://europepmc.org/article/MED/33829355
https://www.ncbi.nlm.nih.gov/pubmed/33829355
https://snucm.elsevierpure.com/en/publications/a-phase-1-dose-escalation-and-dose-expansion-study-to-assess-the-
http://pubmed.ncbi.nlm.nih.gov/33829355/
https://pubmed.ncbi.nlm.nih.gov/33829355/

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Autori: Hisato Kawakami Jeeyun Lee Hyun-Cheol Chung a ďalší

Prispievatelia: Hisato Kawakami Jeeyun Lee Hyun-Cheol Chung a ďalší

Zdroj: New England Journal of Medicine. 382:2419-2430

Predmety: Lung Diseases, Adult, Male, 0301 basic medicine, Immunoconjugates, Camptothecin / analogs & derivatives, Esophageal Neoplasms, Paclitaxel, Receptor, ErbB-2, Humanized / adverse effects, Camptothecin / therapeutic use, Antineoplastic Agents, Stomach Neoplasms / drug therapy, Antineoplastic Agents / therapeutic use, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Irinotecan, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Stomach Neoplasms, Monoclonal, 80 and over, Humans, Irinotecan / therapeutic use, Humanized / therapeutic use, Aged, Aged, 80 and over, Esophageal Neoplasms / drug therapy, Interstitial / chemically induced, Bone Marrow / drug effects, Antineoplastic Agents / adverse effects, Immunoconjugates / adverse effects, Middle Aged, Survival Analysis, Immunoconjugates / therapeutic use, 3. Good health, Adenocarcinoma / drug therapy, Camptothecin / adverse effects, ErbB-2 / analysis, Camptothecin, Female, Paclitaxel / therapeutic use, Lung Diseases, Interstitial, Receptor

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/32469182
https://s-space.snu.ac.kr/handle/10371/173254
https://www.ncbi.nlm.nih.gov/pubmed/32469182
https://pubmed.ncbi.nlm.nih.gov/32469182/
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2004413
https://www.nejm.org/doi/full/10.1056/NEJMoa2004413
https://www.scilit.net/article/0f065665446dafb82b21c79c6d3f6e1b

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

Autori: Yan Shen Shan Chung Pin Li Hyun Jeong Shim a ďalší

Prispievatelia: Yan Shen Shan Chung Pin Li Hyun Jeong Shim a ďalší

Zdroj: Cancer Sci

Predmety: Adult, Male, 0301 basic medicine, Irinotecan / administration & dosage, Endpoint Determination, liposomal irinotecan, Leucovorin, Fluorouracil / therapeutic use, Adenocarcinoma, Irinotecan, 03 medical and health sciences, 0302 clinical medicine, Asian People, metastatic pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Fluorouracil / administration & dosage, Irinotecan / therapeutic use, Neoplasm Metastasis, NAPOLI-1, Aged, Leucovorin / therapeutic use, Aged, 80 and over, clinical trial, Pancreatic Neoplasms / drug therapy, Original Articles, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Leucovorin / administration & dosage, Middle Aged, Survival Analysis, 3. Good health, Asians, Pancreatic Neoplasms, Treatment Outcome, Adenocarcinoma / drug therapy, phase 3, Liposomes, Female, Fluorouracil, Asian subgroup

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31789476
https://europepmc.org/article/PMC/PMC7004519
https://onlinelibrary.wiley.com/doi/10.1111/cas.14264
https://pubmed.ncbi.nlm.nih.gov/31789476/
https://snucm.elsevierpure.com/en/publications/liposomal-irinotecan-in-metastatic-pancreatic-adenocarcinoma-in-a
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004519/
https://s-space.snu.ac.kr/handle/10371/173033

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Autori: Kopetz, S. Grothey, A. Yaeger, R. a ďalší

Prispievatelia: Kopetz, S. Grothey, A. Yaeger, R. a ďalší

Zdroj: RiUVic. Repositori institucional de la UVic-UCC
instname
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075

Predmety: Male, IRINOTECAN, Cetuximab, Kaplan-Meier Estimate, TRAMETINIB, VEMURAFENIB, THERAPY, 0302 clinical medicine, Medicaments -- Assaigs clínics, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Benzimidazoles/administration & dosage, Treatments in Oncology, 11 Medical and Health Sciences, Aged, 80 and over, Sulfonamides, COLON-CANCER, Colorectal Neoplasms/drug therapy, Middle Aged, DABRAFENIB, Intention to Treat Analysis, 3. Good health, Còlon -- Càncer, Disease Progression, Female, Colorectal Neoplasms, Life Sciences & Biomedicine, PROGRESSION-FREE SURVIVAL, Adult, Proto-Oncogene Proteins B-raf, Irinotecan/therapeutic use, INHIBITION, Irinotecan, 03 medical and health sciences, Medicine, General & Internal, Carbamates/administration & dosage, General & Internal Medicine, Proto-Oncogene Proteins B-raf/genetics, Humans, Cetuximab/administration & dosage, Aged, Colorectal Cancer, Sulfonamides/administration & dosage, Science & Technology, 42 Health sciences, MUTATIONS, Antineoplastic Combined Chemotherapy Protocols/adverse effects, 32 Biomedical and clinical sciences, Survival Analysis, Mutation, Benzimidazoles, Carbamates, Electrocorticography, ACQUIRED-RESISTANCE

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31566309
https://pubmed.ncbi.nlm.nih.gov/31566309/
https://portal.findresearcher.sdu.dk/da/publications/encorafenib-binimetinib-and-cetuximab-in-braf-v600emutated-colore
https://mdanderson.elsevierpure.com/en/publications/encorafenib-binimetinib-and-cetuximab-in-braf-v600emutated-colore
https://www.nejm.org/doi/full/10.1056/NEJMoa1908075
https://www.ncbi.nlm.nih.gov/pubmed/31566309
https://www.nejm.org/doi/suppl/10.1056/NEJMoa1908075/suppl_file/nejmoa1908075_appendix.pdf
https://lirias.kuleuven.be/handle/123456789/642210
https://doi.org/10.1056/nejmoa1908075
https://findresearcher.sdu.dk:8443/ws/files/158747483/nejmoa1908075.pdf
https://discovery-pp.ucl.ac.uk/id/eprint/10086190/

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer

Autori: Tae Won Kim Anneli Elme Joon Oh Park a ďalší

Prispievatelia: Tae Won Kim Anneli Elme Joon Oh Park a ďalší

Zdroj: Clinical Colorectal Cancer. 17:206-214

Predmety: Male, Drug Resistance, Anti-EGFR therapy, Biomarkers, Gastrointestinal cancer, Randomized controlled trial, Treatment outcome, Kaplan-Meier Estimate, Adenocarcinoma / pathology, Colorectal Neoplasms / genetics, Palliative Care, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Panitumumab / pharmacology, Prospective Studies, Colorectal Neoplasms / mortality, Irinotecan / therapeutic use, Infusions, Intravenous, Oxaliplatin / therapeutic use, Aged, 80 and over, Irinotecan / pharmacology, Panitumumab, Adenocarcinoma / genetics, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Neoplasm / genetics, Middle Aged, Proto-Oncogene Proteins B-raf / genetics, Progression-Free Survival, 3. Good health, Oxaliplatin, Disease Progression, Female, Intravenous, Colorectal Neoplasms, Adult, Colorectal Neoplasms / therapy, Infusions, Adenocarcinoma, Irinotecan, Colorectal Neoplasms / pathology, Adenocarcinoma / mortality, Young Adult, 03 medical and health sciences, Tumor Burden / drug effects, Adenocarcinoma / therapy, Humans, Antineoplastic Combined Chemotherapy Protocols / pharmacology, Proto-Oncogene Proteins p21(ras) / genetics, Aged, Drug Resistance, Neoplasm, Oxaliplatin / pharmacology, Mutation, Panitumumab / therapeutic use, Follow-Up Studies

Prístupová URL adresa: http://www.clinical-colorectal-cancer.com/article/S1533002817305297/pdf
https://pubmed.ncbi.nlm.nih.gov/29703606
https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802226915309157
https://www.ncbi.nlm.nih.gov/pubmed/29703606
https://www.sciencedirect.com/science/article/pii/S1533002817305297
https://www.sciencedirect.com/science/article/abs/pii/S1533002817305297#!
https://www.sciencedirect.com/science/article/pii/S1533002817305297#!
https://pubmed.ncbi.nlm.nih.gov/29703606/

Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

Autori: Jakobsen, J N Urup, T Grunnet, K a ďalší

Zdroj: Journal of Neuro-Oncology. 137:439-446

Predmety: Adult, Male, 0301 basic medicine, Irinotecan/therapeutic use, Lomustine/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/toxicity, Antineoplastic Agents, Brain Neoplasms/drug therapy, Irinotecan, Bevacizumab/therapeutic use, Local/drug therapy, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological/therapeutic use, Lomustine, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Salvage Therapy, Brain Neoplasms, Middle Aged, Glioblastoma/drug therapy, 3. Good health, Bevacizumab, Neoplasm Recurrence, Treatment Outcome, Female, Neoplasm Recurrence, Local, Glioblastoma, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/29330749
https://link.springer.com/content/pdf/10.1007%2Fs11060-017-2736-x.pdf
https://pubmed.ncbi.nlm.nih.gov/29330749/
https://europepmc.org/article/MED/29330749
https://www.ncbi.nlm.nih.gov/pubmed/29330749

Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis

Autori: Dutch Pancreatic Cancer Group Zorgeenheid Vaatchirurgie Zorg MS CGO a ďalší

Prispievatelia: Dutch Pancreatic Cancer Group Zorgeenheid Vaatchirurgie Zorg MS CGO a ďalší

Predmety: Male, Oxaliplatin/therapeutic use, Irinotecan/therapeutic use, Locally advanced pancreatic cancer, Netherlands/epidemiology, Pancreas/pathology, Fluorouracil/therapeutic use, Journal Article, Humans, Pancreatic Neoplasms/diagnosis, Prospective Studies, resection, Propensity Score, Neoplasm Staging, Survival Rate/trends, Leucovorin/therapeutic use, Antineoplastic Agents/therapeutic use, Middle Aged, Resection, locally advanced pancreatic cancer, FOLFIRINOX, Pancreatectomy/methods, Multicenter Study, Female, Surgery, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://dspace.library.uu.nl/handle/1874/444533

NET-02 trial protocol:A multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

Autori: Craig, Zoe Swain, Jayne Batman, Emma a ďalší

Zdroj: Craig, Z, Swain, J, Batman, E, Wadsley, J, Reed, N, Faluyi, O, Cave, J, Rohini, S, Chau, I, Wall, L, Lamarca, A, Hubner, R, Mansoor, W, Sarker, D, Meyer, T, Cairns, D A, Howard, H, Valle, J & Mcnamara, M 2020, 'NET-02 trial protocol : A multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)', BMJ Open, vol. 10, no. 2, e034527, pp. e034527. https://doi.org/10.1136/bmjopen-2019-034527

Predmety: Neuroendocrine carcinoma, randomised, single-stage, liposomal irinotecan, docetaxel, Humans, Irinotecan/therapeutic use, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Docetaxel/therapeutic use, Fluorouracil/therapeutic use, Multicenter Studies as Topic, Carcinoma, Neuroendocrine/drug therapy, Quality of Life, Clinical Trials, Phase II as Topic, Leucovorin/therapeutic use, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre

Dostupnosť: https://research.manchester.ac.uk/en/publications/3e3acd38-1452-45c5-bc7c-2c1e3a9d7e80
https://doi.org/10.1136/bmjopen-2019-034527
http://www.scopus.com/inward/record.url?scp=85079084289&partnerID=8YFLogxK
https://www.mendeley.com/catalogue/6f29ece9-cc63-3686-a0e4-3343b118dc3b/

Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis.

Autori: Voutsadakis, I.A. Kokkali, S. Digklia, A.

Predmety: Humans, Irinotecan/therapeutic use, Irinotecan/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil/therapeutic use, Fluorouracil/administration & dosage, Deoxycytidine/analogs & derivatives, Deoxycytidine/administration & dosage, Deoxycytidine/therapeutic use, Biliary Tract Neoplasms/drug therapy, Biliary Tract Neoplasms/pathology, Biliary Tract Neoplasms/mortality, Gemcitabine, Disease Progression, Progression-Free Survival, Biliary tract adenocarcinoma, CAPIRI, Cholangiocarcinoma, FOLFIRI, Second line

Relation: Clinical Colorectal Cancer; https://iris.unil.ch/handle/iris/140528; serval:BIB_B150D8B52D32

Dostupnosť: https://iris.unil.ch/handle/iris/140528
https://doi.org/10.1016/j.clcc.2024.05.009

Modern Management of Small-Cell Lung Cancer

Autori: Ferraldeschi, Roberta Baka, Sofia Jyoti, Babita a ďalší

Zdroj: Ferraldeschi, R, Baka, S, Jyoti, B, Faivre-Finn, C, Thatcher, N & Lorigan, P 2007, 'Modern management of small-cell lung cancer', Drugs, vol. 67, no. 15, pp. 2135-2152.

Predmety: Lung Neoplasms, Paclitaxel, Irinotecan, therapeutic use, Small cell lung cancer, treatment, Antineoplastic Agents, Pemetrexed, Etoposide, therapeutic use, Irinotecan, Carboplatin, 03 medical and health sciences, 0302 clinical medicine, Paclitaxel, therapeutic use, Animals, Humans, Carcinoma, Small Cell, Karnofsky Performance Status, Etoposide, Aged, Small cell lung cancer, treatment, Carboplatin, therapeutic use, Prognosis, Combined Modality Therapy, 3. Good health, Amrubicin, therapeutic use, Pemetrexed, therapeutic use, Drug Resistance, Neoplasm, therapeutic use, Immunotherapy, Cisplatin, Neoplasm Recurrence, Local, Amrubicin, Cisplatin, therapeutic use

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/17927281
https://research.manchester.ac.uk/en/publications/ffb17f05-b392-4f55-b3fc-46d9f6c46f0c
https://europepmc.org/article/MED/17927281
https://www.research.manchester.ac.uk/portal/en/publications/modern-management-of-smallcell-lung-cancer(ffb17f05-b392-4f55-b3fc-46d9f6c46f0c)/export.html
https://link.springer.com/article/10.2165/00003495-200767150-00003
http://christie.openrepository.com/christie/handle/10541/70061
https://www.escholar.manchester.ac.uk/uk-ac-man-scw:1d31424
https://pubmed.ncbi.nlm.nih.gov/17927281/

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)

Autori: Keun‐Wook Lee Chi Hoon Maeng Tae‐You Kim a ďalší

Prispievatelia: Keun‐Wook Lee Chi Hoon Maeng Tae‐You Kim a ďalší

Zdroj: Oncologist

Predmety: Adult, Male, Paclitaxel, Antineoplastic Agents, Irinotecan / therapeutic use, Stomach Neoplasms / drug therapy, Irinotecan, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, 80 and over, Humans, Phytogenic / pharmacology, Neoplasm Metastasis, Aged, Paclitaxel / therapeutic use, Aged, 80 and over, Irinotecan / pharmacology, Clinical Trial Results, Paclitaxel / pharmacology, Middle Aged, Antineoplastic Agents, Phytogenic, Phytogenic / therapeutic use, 3. Good health, Female, Stomach Neoplasms / pathology

Prístupová URL adresa: https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0142
https://pubmed.ncbi.nlm.nih.gov/30126861
http://theoncologist.alphamedpress.org/content/24/1/18.long
https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2018-0142
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324622
https://koreauniv.pure.elsevier.com/en/publications/a-phase-iii-study-to-compare-the-efficacy-and-safety-of-paclitaxe
https://europepmc.org/abstract/MED/30126861
https://theoncologist.onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2018-0142
https://www.annalsofoncology.org/article/S0923-7534(19)49142-4/fulltext